Asia-Pacific cancer monoclonal antibodies market is estimated to grow at a CAGR of 11.2% during the forecast period. Increasing awareness regarding cancer is one of the pivotal factors accelerating market growth. Biopharmaceutical firms have reported the launch of public awareness campaigns for cancer. For instance, in May 2016 Roche launched a public awareness campaign known as ‘Run for Her’. This campaign aims to deliver successfully crucial messages regarding the need for breast cancer screening in women frequently. Early diagnosis and consistent treatment can lead to improving disease outcomes and quality of life of breast cancer patients.
To Request a Sample of our Report on Asia-Pacific Cancer Monoclonal Antibodies Market: https://www.omrglobal.com/request-sample/asia-pacific-cancer-monoclonal-antibodies-market
The company organized this campaign in collaboration with the China Cancer Rehabilitation Society, to increase public awareness regarding breast cancer. This initiative can support improving awareness, testing, and therapeutics of breast cancer in China, which in turn, will accelerate the demand for monoclonal antibody treatment that serves as one of the established therapeutic strategies for both solid tumors and hematologic malignancies. It is a type of immunotherapy that stimulates the immune system of cancer patients and works to recognize and attack cancer cells.
Scope of the Asia-Pacific Cancer Monoclonal Antibodies Market
· Market Coverage
· Market number available for 2019-2026
· Base year- 2019
· Forecast period- 2020-2026
· Segment Covered- By Type and Application
· Regions Covered- China, India, Japan, and Rest of Asia-Pacific
· Competitive Landscape- Biocon Ltd., Amgen Inc., F. Hoffman La-Roche AG, Pfizer Inc., and Mylan N.V.
Recent Strategic Initiatives in the Asia-Pacific Cancer Monoclonal Antibodies Market
· In July 2020, Ahmedabad-based Cadila Pharmaceuticals Ltd. declared the introduction of biosimilar Rituximab in India. It is indicated for the treatment of rheumatoid arthritis and blood cancer launched within the brand name Ritucad. It is used to treat Non-Hodgkin’s lymphoma (a type of blood-related cancer). According to the company, over 28,000 new cases of Lymphoma are reported each year in India. This launch will increase the accessibility of cancer treatment in the country.
· In October 2019, Amgen declared collaboration with BeiGene that will further widen Amgen’s plans to enhance its oncology presence in China. Under the agreement, BeiGene will commercialize BLINCYTO (blinatumomab), XGEVA (denosumab), and KYPROLIS (carfilzomib) in China. Additionally, this acquisition will also support Amgen for the commercialization of its non-oncology product portfolio in China.
(Get 15% Discount on Buying this Report)
A full Report of Asia-Pacific Cancer Monoclonal Antibodies Market is Available at: https://www.omrglobal.com/industry-reports/asia-pacific-cancer-monoclonal-antibodies-market
Key questions addressed by the report
· What is the market growth rate?
· Which segment dominates the market in the base year?
· Which segment will project the fastest growth in the market?
· How COVID-19 impacted the market?
Ø Recovery Timeline
Ø Deviation from the pre-COVID forecast
Ø Most affected segment
· Who is the leader in the market?
· How players are addressing challenges to sustain growth?
· Where is the investment opportunity?
Asia-Pacific Cancer Monoclonal Antibodies Market-Segmentation
By Type
· Naked
· Conjugated
· Others (Bispecific)
By Application
· Breast Cancer
· Liver Cancer
· Blood Cancer
· Brain Cancer
· Colorectal Cancer
· Others
(This release has been published on OMR Industry Journal. OMR Industry Journal is not responsible for any content included in this release.)
